儿童心脏骤停后24小时与72小时低温治疗:一项先导性随机对照试验
该单中心先导性随机对照试验纳入34例心脏骤停后昏迷、由医生实施低温治疗(33±1°C)的1周至17岁儿童,比较24小时与72小时低温疗程。两组患者特征、基线生物标志物浓度及不良事件相似;24小时组与72小时组死亡分别为8例(47%)与4例(24%),p=0.3。24小时组血清神经元特异性烯醇化酶(NSE)在84-96小时及第7天高于72小时组,S100b在12-24小时、36-84小时及第7天均高于72小时组(均p<0.05)。作者认为生物标志物有望作为儿童心脏骤停的诊疗工具,72小时疗程值得进一步探索。
要点
- 儿童心脏骤停后昏迷、由医生实施低温治疗者,72小时组(33±1°C)第7天NSE中位数2.6 ng/ml,低于24小时组18.2 ng/ml(p=0.047)。
- 24小时组84-96小时NSE中位数47.7 ng/ml,高于72小时组1.4 ng/ml(p=0.02)。
- 24小时组S100b在12-24小时、36-84小时及第7天均高于72小时组,均p<0.05。
- 24小时组死亡8例(47%),72小时组死亡4例(24%),p=0.3,无显著差异。
- 多因素分析中低温疗程与第7天S100b浓度相关,但与NSE或MBP无关。
适用人群与场景
- 心脏骤停后恢复循环但仍昏迷、年龄1周至17岁、由其医生实施低温治疗的儿童;单中心先导性随机试验。
处置流程与药物剂量
- 低温治疗目标温度33±1°C,随机分为24小时或72小时疗程。
- 第1-4天每日采集血清两次,第7天采集一次;6个月时评估死亡。
研究设计与关键结果
- 单中心先导性随机对照试验,纳入34例儿童心脏骤停后昏迷患者,比较24小时与72小时低温(33±1°C)疗程。
- 两组患者特征、基线生物标志物浓度及不良事件相似。
- 24小时组死亡8例(47%),72小时组死亡4例(24%),p=0.3。
- 84-96小时NSE中位数24小时组47.7(3.9, 79.9)ng/ml vs 72小时组1.4(0.0, 11.1)ng/ml,p=0.02。
- 第7天NSE中位数24小时组18.2(3.2, 74.0)ng/ml vs 72小时组2.6(0.0, 12.8)ng/ml,p=0.047。
- S100b在12-24小时、36-84小时及第7天24小时组均高于72小时组,均p<0.05。
- 多因素分析显示低温疗程与第7天S100b浓度相关,但与NSE或MBP无关。
证据类型、等级与局限
- 证据类型:单中心先导性随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为血清生物标志物有望作为儿童心脏骤停的诊疗工具。
- 作者的生物标志物与安全性数据提示,儿童心脏骤停后72小时低温疗程值得进一步探索。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: Children surviving cardiac arrest (CA) lack proven neuroprotective therapies. The role of biomarkers in assessing response to interventions is unknown. We hypothesized that 72 versus 24 h of hypothermia (HT) would produce more favorable biomarker profiles after pediatric CA.
METHODS: This single center pilot randomized trial tested HT (33 ± 1 °C) for 24 vs. 72 h in 34 children with CA. Children comatose after return of circulation aged 1 week to 17 years and treated with HT by their physician were eligible. Serum was collected twice daily on days 1-4 and once on day 7. Mortality was assessed at 6 months.
RESULTS: Patient characteristics, baseline biomarker concentrations, and adverse events were similar between groups. Eight (47%) and 4 (24%) children died in the 24 h and 72 h groups, p = .3. Serum neuron specific enolase (NSE) concentration was increased in the 24 vs. 72 h group at 84 h-96 h (median [interquartile range] 47.7 [3.9, 79.9] vs. 1.4 [0.0, 11.1] ng/ml, p = .02) and on day 7 (18.2 [3.2, 74.0] vs. 2.6 [0.0, 12.8] ng/ml, p = .047). Serum S100b was increased in the 24 h vs. 72 h group at 12 h-24 h, 36 h-84 h, and on day 7, all p < 0.05. HT duration was associated with S100b (but not NSE or MBP) concentration on day 7 in multivariate analyses.
CONCLUSION: Serum biomarkers show promise as theragnostic tools in pediatric CA. Our biomarker and safety data also suggest that 72 h duration after pediatric CA warrants additional exploration.
参考来源
- Fink EL, Clark RSB, Berger RP, et al. 24 vs. 72 hours of hypothermia for pediatric cardiac arrest: A pilot, randomized controlled trial. Resuscitation. 2018. PMID: 29454009. doi:10.1016/j.resuscitation.2018.02.008
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。